Table 1.
Demographic, clinicopathologic, and treatment trends
| Characteristics | Decade A group (n = 116) (%)a | Decade B group (n = 203) (%)a | P-value |
|---|---|---|---|
| Age (year) | <0.001 | ||
| <70 | 105 (90.5) | 147 (72.4) | |
| ≥70 | 11 (9.5) | 56 (27.6) | |
| Parity | 0.66 | ||
| 0 | 22 (19.0) | 43 (21.2) | |
| 1–2 | 62 (53.4) | 113 (55.7) | |
| ≥3 | 32 (27.6) | 47 (23.1) | |
| Body mass index | 0.40 | ||
| <25 | 83 (71.6) | 136 (67.0) | |
| ≥25 | 33 (28.4) | 67 (33.0) | |
| Pelvic lymphadenectomy | 99 (85.3) | 170 (83.7) | 0.24 |
| Para-aortic lymph node sampling | 39 (33.6) | 103 (50.7) | <0.01 |
| Median number of nodes (range) | |||
| Pelvic | 14 (1–40) | 13 (1–47) | |
| Para-aortic | 1 (1–7) | 1 (1–14) | |
| Positive lymph nodeb | 0.88 | ||
| Pelvic | 12 (10.3) | 12 (5.9) | |
| Para-aortic | 2 (1.7) | 4 (2.0) | |
| Pelvic and para-aortic | 1 (0.9) | 11 (5.4) | |
| Surgical stagec | 0.30 | ||
| IA | 71 (61.2) | 109 (53.7) | |
| IB | 14 (12.1) | 24 (11.8) | |
| II | 4 (3.4) | 11 (5.4) | |
| IIIA | 7 (6.0) | 19 (9.4) | |
| IIIB | 1 (0.9) | 2 (1.0) | |
| IIIC1 | 9 (7.8) | 12 (5.9) | |
| IIIC2 | 4 (3.4) | 11 (5.4) | |
| IV | 6 (5.2) | 15 (7.4) | |
| Myometrial invasion | 0.59 | ||
| < 1/2 | 80 (69.0) | 134 (66.0) | |
| ≥ 1/2 | 36 (31.0) | 69 (34.0) | |
| Histologyd | 0.01 | ||
| Endometrioid | |||
| Grade 1 | 59 (50.8) | 88 (43.4) | |
| Grade 2 | 32 (27.6) | 45 (22.2) | |
| Grade 3 | 13 (11.2) | 26 (12.8) | |
| Serous | 6 (5.2) | 24 (11.8) | |
| Clear cell | 1 (0.9) | 7 (3.4) | |
| Carcinosarcoma | 5 (4.3) | 13 (6.4) | |
| Adjuvant chemotherapy | 39 (33.6) | 89 (43.8) | 0.04 |
| Adjuvant radiotherapy | 5 (4.3) | 7 (3.4) | 0.70 |
Notes:
a
Percent denotes proportion of patients during decade;
b
cases with lymph node metastasis versus cases without lymph node metastasis;
c
stages I and II versus stages III and IV;
d
endometrioid versus serous carcinoma, clear cell carcinoma, and carcinosarcoma.